Keywords
Early biomarkers, neurodegenerative disorders, Parkinson’s disease; CD4+ T lymphocytes; Transcription factors; Gene expression
This article is included in the Cell & Molecular Biology gateway.
This article is included in the Bioinformatics gateway.
This article is included in the Retinal Physiology collection.
In this datanote we present data from 31 iRBD (idiopathic Rapid eye movement (REM) sleep Behaviour Disorder) patients followed throughout three years to assess their eventual phenoconversion to Parkinson’s disease and other established neurodegenerative conditions. iRBD is a prodromal condition of neurological pathologies such as Parkinson’s disease. We evaluated transcription factor mRNA levels in CD4+ T cells as predictive biomarkers of phenoconversion in iRBD, showing that among the transcription factors mRNA levels analysed, STAT1, GATA3 and FOXP3 mRNA levels may be used to predict phenoconversion. In particular, we found that CD4+ T cells from converters had higher STAT1, and lower GATA3 and FOXP3 mRNA levels. According to ROC curve analysis STAT1 levels provided a good discrimination, GATA3 levels an excellent discrimination of future converters and not-converters, while discrimination provided by FOXP3 levels was acceptable.
Early biomarkers, neurodegenerative disorders, Parkinson’s disease; CD4+ T lymphocytes; Transcription factors; Gene expression
In the present version, the title has been modified to make it more consistent with the content of the study, the abstract has been expanded to include a summary of the main results and the introduction has been reworked to better highlight the innovative nature of the research ad its connection to our previous publications.
See the authors' detailed response to the review by Tommaso Schirinzi
See the authors' detailed response to the review by Adawiya J. Haider
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a REM-phase parasomnia, typically associated with neurodegenerative disorders (38-75%1,2). iRBD (idiopathic Rapid eye movement (REM) sleep Behaviour Disorder) is a prodromal condition in the process underlying synucleinopathies, including Parkinson’s disease (PD). The risk for PD conversion in people with iRBD is estimated around 43% at five years.3
The data included here are from a study3 that evaluated whether transcription factor genes TBX21, STAT1, STAT3, STAT4, STAT6, RORC, GATA3, FOXP3, and NR4A2 mRNA levels in CD4+ T cells could represent predictive biomarkers of phenoconversion in iRBD patients. To this end, we performed a follow-up of the iRBD subjects enrolled in previous research,4 with the aim to identify three years later who was eventually phenoconverted towards a frank neurodegenerative condition. The study by Di Francesco et al. (2021)4 showed that in iRBD subjects CD4+ T cells exhibit a peculiar molecular signature strongly resembling cells from PD patients, while the study by Pinoli et al. (2024)5 thereafter revealed that STAT1, GATA3 and FOXP3 mRNA levels in CD4+ T cells are promising predictive biomarkers of phenoconversion in iRBD patients.
Indeed, converters showed higher expression levels of STAT1, and lower levels of GATA3 and FOXP3. We also found higher percentages of monocytes in converters versus not converters. The implications of these transcription factors in the neuroinflammatory process are clearly evinced also from the contribution they make to the differentiation of Th1 (STAT1), Th2 (GATA3) and Treg (FOXP3) phenotypes. Namely, it was demonstrated that peripheral blood of PD patients had increased Th1 and decreased Th2 and Treg.6
We decided to focus on the study of molecular markers to identify early variations that could allow us to identify individuals who will develop PD, before lesions develop. Future studies will be necessary to further explore the role of these markers and subsequently develop targeted drugs for tailored therapy.
Data reported in this paper have been previously analysed in Pinoli et al. (2024) and De Francesco et al. (2021).
The Ethics Committee of the Neurological Institute “C. Mondino” of Pavia approved the protocol (number 2021008499, 10/02/2021) and all the participants signed a written informed consent before enrolment.
31 patients were followed at the Sleep Center of the Neurological Institute “C. Mondino” of Pavia. The clinical evaluation included: motor symptoms, assessed by means of the Unified Parkinson’s Disease Rating Scale (UPDRS) part III7; cognitive function, by the Mini Mental State Examination (MMSE)8,9; constipation and orthostatic hypotension by means of the Scale for Outcomes in Parkinson’s disease-Autonomic (SCOPA-AUT)7; depressive symptoms, by means of the Hamilton Rating Scale for Depression (HAM-D).10
At the original enrolment,5 each patient provided a venous blood sample, which was processed to isolate CD4+ T cells, according to an established procedure.6
Subjects with iRBD were followed prospectively with periodic in-person evaluations to diagnose phenoconversion, i.e., parkinsonism, DLB and MSA.
Peripheral blood mononuclear cells were separated by Ficoll-Paque Plus density gradient centrifugation; then CD4+ T cells were obtained by immunomagnetic sorting. Cell viability was 95% ± 1% (range, 90%–98%), and purity was 98% ± 2% (range, 97%–100%). Expression of the TF genes TBX21, STAT1, STAT3, STAT4, STAT6, RORC, GATA3, FOXP3, and NR4A2 was measured by real-time polymerase chain reaction.
For real-time PCR assays of CD4+ T cells, at least 50,000 CD4+ T cells were resuspended in PerfectPure RNA lysis buffer (5 Prime GmbH, Hamburg, Germany), and total RNA was extracted by PerfectPure RNA Cell Kit™ (5 Prime GmbH, code 2302340). The amount of extracted RNA was estimated by spectrophotometry at λ = 260 nm. Total mRNA was then reverse-transcribed using a random primer and a high-capacity cDNA RT kit (Applied Biosystems, code 4368813), and the resulting amount of cDNA was estimated by spectrophotometry at λ = 260 nm. Real-Time PCR reactions were then started with 1 μM cDNA. At the beginning, we always loaded 1 μg/μl of cDNA per reaction (final reaction mix volume + sample = 20 μl). This means that for each reaction we load 2 μl of aqueous solution containing the cDNA (therefore, 2 μg of cDNA in total). The following thermal protocol was used for each sample: 20 s at 95°C (x 1, hot start); 2-step cycles as follows: 1 s at 95°C, 20 s at 60°C (x 40). All the reagents (probes and mix) were used according to the manufacturer’s instructions (www.bio-rad.com).
FigShare: “The importance of early biomarkers in the identification of neurodegenerative disorders”. Doi: 10.6084/m9.figshare.2860390711
The project contains the following underlying data:
• Raw data of patients collected during enrolment and follow-up (.xls)
• Patients were labeled with an anonymized sample ID number.
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
The authors wish to thank all the patients and their relatives and caregivers who accepted to be enrolled in the study, as well as all the nurses and colleagues who helped in recruitment, clinical assessment and collection of demographic and clinical data. The authors wish to express their gratefulness to Doctor Gaetano Malomo, MD, Department of Brain and Behavioral Sciences, University of Pavia, Pavia (I), who is responsible for updating and maintaining the iRBD patients archive, and to Professor Giovanni Veronesi, MD, PhD, Department of Medicine and Surgery, University of Insubria, Varese (I), who kindly supervised in part the statistical analysis.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Is the rationale for creating the dataset(s) clearly described?
No
Are the protocols appropriate and is the work technically sound?
No
Are sufficient details of methods and materials provided to allow replication by others?
No
Are the datasets clearly presented in a useable and accessible format?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Nanotechnology
Is the rationale for creating the dataset(s) clearly described?
Partly
Are the protocols appropriate and is the work technically sound?
Yes
Are sufficient details of methods and materials provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Biological issues of PD and movement disorders
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 06 Oct 25 |
read | |
Version 1 10 Jul 25 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)